Veliparib and other PARP inhibitors are currently undergoing clinical evaluation in different tumor types in combination with agents such as paclitaxel/carboplatin, cisplatin/gemcitabine, topotecan, cyclophosphamide, and temozolamide [15–18]. Here, PARP1 is linked to neoplasm.